Corbus Pharmaceuticals Announces Board Changes and New Compensation Plans

Corbus Pharmaceuticals (CRBP) has issued an announcement.

Avery W. Catlin has stepped down from the Board of Directors at Corbus Pharmaceuticals Holdings, Inc., also relinquishing roles on the Audit and Compensation Committees without citing disagreements. In his stead, Winston W. Kung, with a robust background in biopharmaceutical finance and corporate governance, has been appointed to the Board, the Audit Committee Chair, and is recognized as an audit committee financial expert. Kung’s appointment comes with a compensation plan including stock options, cash retainers, and equity awards, and is backed by an indemnification agreement to cover legal expenses incurred during service.

See more insights into CRBP stock on TipRanks’ Stock Analysis page.